BioCentury
ARTICLE | Clinical News

Adenuric febuxostat regulatory update

May 12, 2008 7:00 AM UTC

The EC approved an MAA from Ipsen for Adenuric febuxostat 80 and 120 mg tablets to treat chronic hyperuricemia in gout. Ipsen has European development and marketing rights to the selective xanthine o...